{"classes":[{"categories":[{"measurements":[{"comment":"The upper limit of the CI is not estimable due to a low number of events","groupId":"OG000","lowerLimit":"17.2","upperLimit":"NA","value":"22.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"21"}],"units":"Participants"}],"description":"The median time to progression will be estimated using the method of Kaplan-Meier. Categorized by Response Assessment Criteria as specified in Appendix III of the protocol.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive ixazomib citrate PO on days 1, 8, and 15 and ibrutinib PO daily on days 1-28. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity.\n\n\\>\n\n\\> Ibrutinib: Given PO\n\n\\>\n\n\\> Ixazomib Citrate: Given PO\n\n\\>\n\n\\> Laboratory Biomarker Analysis: Correlative studies\n\n\\>\n\n\\> Pharmacodynamic Study: Correlative studies\n\n\\>\n\n\\> Pharmacokinetic Study: Correlative studies","id":"OG000","title":"Treatment (Ixazomib Citrate, Ibrutinib)"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"From study registration to the earliest date of documentation of disease progression, assessed up to 5 years","title":"Progression-free Survival","type":"SECONDARY","unitOfMeasure":"months"}